Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Un Kwon-Casado, Geert Nygaard, Thomas Taapken, Uwe Staub, Yitzhak Peterburg

Premium

Fluidigm has promoted Un Kwon-Casado to the position of vice president of corporate development, the company said.
Kwon-Casado has served as director of strategic marketing at Fluidigm since October 2009. Prior to that she was vice president of healthcare equity research for Pacific Growth Equities.


Epigenomics disclosed last week that company CEO Geert Nygaard left the firm as of Sept. 30, and that Thomas Taapken has been appointed as sole member of the company's executive board, effective Oct. 1.

Taapken previously served as chief financial officer at Epigenomics, a position he held since April 2011. He joined Epigenomics from Biotie Therapies in Finland, where he also served as CFO. He was appointed to that position in 2008, following a merger between Biotie Therapies and Elbion, where Taapken had been CFO since 2005. He has also held positions as an investment partner at Deutsche Venture Capital and Burrill & Company. Taapken also worked several years at Sanofi-Aventis.

Epigenomics also disclosed that it has promoted Uwe Staub, former senior vice president of research and development, to the position of chief operating officer.


Rosetta Genomics has nominated Yitzhak Peterburg to serve on the company's board of directors and has called a shareholder meeting to approve the appointment. If approved, he will be the seventh member of Rosetta Genomics' board.

Peterburg formerly was senior vice president and head of Global Branded Products at Teva Pharmaceuticals, where he currently is a board member. He also was general manager at Clalit Health Services, an Israeli non-government, non-profit comprehensive health services organization, and he was CEO of Soroka University Medical Center.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.